Major Developments
YOFC (06869) announced that its subsidiary plans to invest 170 million yuan to co-establish the Changfei Smart Fund. CN INT DEV CORP (00264) has signed a procurement contract for prefabricated AI data center modules. CStone Pharmaceuticals-B (02171) reported that its drug CT0596 has received IND approval from the National Medical Products Administration for treating relapsed/refractory multiple myeloma (R/R MM) patients. Jiangsu Hengrui Medicine-B (09966) has entered into a licensing agreement with PATHOS AI for JSKN016. Sino Biopharmaceutical (01177) announced that its drug TQB2102, a "HER2 bispecific antibody ADC," has been included in the CDE's Breakthrough Therapy Designation list for the third time. Shanghai Fosun Pharmaceutical (02196) received approval from the National Medical Products Administration for its drug registration application of compound polyethylene glycol (3350) electrolyte powder. Additionally, Shanghai Fosun Pharmaceutical (02196) obtained approval for the registration of empagliflozin and metformin hydrochloride extended-release tablets (III). CSPC Pharmaceutical Group (01093) announced that the first research center in China has officially initiated the Phase Ib/II clinical trial of its SYS 6090 injection for treating colorectal cancer. SSY Group (02005) reported that all 13 varieties and 16 specifications of its bid products were selected for the national centralized drug procurement. Fusen Pharmaceutical (01652) announced that four of its products were selected in the national centralized drug procurement. Shanghai Pharmaceuticals (02607) received approval for producing omeprazole and sodium bicarbonate dry suspension (I). Yinuo Pharmaceutical-B (02591) obtained PIC/S GMP certificates for two entrusted production sites of its Yisupaglu alpha injection. Jiangsu Hengrui Medicine-B (09966) received CDE approval to conduct a Phase III clinical study for JSKN033 in treating cervical cancer. Maike Pharmaceutical-B (02335) announced that the Phase II clinical trial of MT200605 for treating acute ischemic stroke (AIS) has met its primary endpoint.
Bond Notes
Guangzhou Automobile Group (02238) plans to apply for registration and issuance of debt financing instruments with a total principal amount not exceeding 15 billion yuan.
Share Buybacks/Changes in Holdings
Huaqin Technology (03296) spent 60.03 million yuan on August 3 to repurchase 808,000 A-shares. Midea Group (00300) spent approximately 50.76 million yuan on August 3 to repurchase 588,300 A-shares. Xiaomi Corporation-W (01810) spent 49.96 million Hong Kong dollars on August 3 to repurchase 1.788 million shares. Montage Technology (06809) spent 39.21 million yuan on August 3 to repurchase 205,000 A-shares. Jiangsu Hengrui Medicine (01276) spent 33.74 million yuan on August 3 to repurchase 637,000 A-shares. Sanhuan Group (06951) spent 19.31 million yuan on August 3 to repurchase 172,700 A-shares.
Operational Results
Wuxi AppTec (02359) released its mid-year results, reporting net profit attributable to the parent company of approximately 11.08 billion yuan, representing a 33.7% year-on-year increase. The company declared a dividend of 5.1 yuan per 10 shares, with accelerated globalization and AI-driven R&D as dual engines. Green Jade Games (06633) expects its net profit for the first half of the year to surge by 320% to 361% year-on-year. XPeng Inc.-W (09868) delivered approximately 38,000 new vehicles in July, a 4% year-on-year increase. SERES (09927) produced approximately 27,600 vehicles and sold approximately 26,700 vehicles in July. SF Intra-City (09699) issued a profit alert, expecting a year-on-year increase in profit attributable to shareholders for the first half of the year of no less than 120%. China Cinda Asset Management (01359) issued a profit warning, expecting a 60% to 70% year-on-year decline in its mid-term net profit attributable to shareholders.
Comments